Executive interview – VolitionRx

Published on 18 July 2017

Volition America, a wholly owned subsidiary of VolitionRx Limited, announces a major new colorectal cancer screening trial with 13,500 patients. In collaboration with the Great Lakes New England Clinical Validation Center and funded by the US National Cancer Institute’s (NCI) Early Detection Research Network (EDRN), this clinical study will seek to validate a panel of biomarkers that include Volition’s Nu.Q Colorectal Cancer Screening test in a large asymptomatic population to support US regulatory approval.

Volition’s chief executive officer, Cameron Reynolds, commented, “This is exciting news for Volition and very much advances our efforts in the US market. We believe this large-scale clinical study will be invaluable when we seek FDA approval for Nu.Q. The public-private arrangement involves joint governmental and private funding and reduces our costs to $3m, and we believe that it represents exceptional value for money. We are delighted to work with US institutions and the US National Cancer Institute with such outstanding reputations, which share our aims in improving early diagnosis of cancer.

Share this with friends and colleagues